PT  - JOURNAL ARTICLE
AU  - Lin, C.-T.
AU  - Yen, T.-C.
AU  - Chang, T.-C.
AU  - Ng, K.-K.
AU  - Tsai, C.-S.
AU  - Ho, K.-C.
AU  - Lai, C.-H.
TI  - Role of [<sup>18</sup>F]fluoro-2-deoxy-D-glucose positron emission tomography in re-recurrent cervical cancer
AID  - 10.1111/j.1525-1438.2006.00729.x
DP  - 2006 Oct 01
TA  - International Journal of Gynecologic Cancer
PG  - 1994--2003
VI  - 16
IP  - 6
4099  - http://ijgc.bmj.com/content/16/6/1994.short
4100  - http://ijgc.bmj.com/content/16/6/1994.full
SO  - Int J Gynecol Cancer2006 Oct 01; 16
AB  - Cervical cancer patients with histologically documented re-recurrence after curative salvage therapy or unexplained tumor marker elevation (negative computed tomography and/or magnetic resonance imaging [CT-MRI]) proven to be a re-recurrence when a further attempt for cure (or control of cancer) appeared feasible were enrolled. Lesion status was determined from pathology or clinical follow-up for at least 12 months. Management decisions were recorded with CT-MRI alone and incorporating [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET), respectively. The benefits calculated were based on clinical impact because of the FDG-PET findings. Cox proportional hazards model was used to select independent prognostic covariates. Of the 26 patients who were eligible for analysis, 12 (46.2%) patients had positive impacts due to PET. Squamous cell carcinoma (SCC, P= 0.029), re-recurrence at distant metastasis only (P= 0.012), and level of SCC antigen ≤4 ng/mL (P= 0.005) were significantly associated with better survival. A scoring system using these covariates defined three distinct prognostic groups (P= 0.0001). Patients with score 0 had a 36-month cumulative survival rate of 80%. Using this prognostic scoring system, FDG-PET may facilitate selecting appropriate management for the individual patient with re-recurrent cervical cancer.